Leveraging Metabolomics to Assess the Next Generation o e for Glioblastoma

of surgery, radiotherapy and chemotherapy with the alkylating agent temozolomide. Several mech-opment with a particular emphasis placed on recent therapeutic advances made in the field. Our aggressive primary brain tumor [1]. It accounts for approxi-the United States [2]. Although early symptoms associated zures [3]. Despite recent progresses in the molecular character-ization of GBMs, median survival time of patients suffering from GBMs remains between 12 and 15 months [4,5]. Current standard of care to treat GBM patients consists of surgical resection followed by a regimen that includes radiotherapy plus concurrent and adjuvant chemotherapeutic treatment with temozolomide (TMZ) [6,7]. TMZ is a DNA alkylating agent of the imidazotetrazine class that can effectively cross the blood–brain barrier [8]. Researchers have started to * Corresponding author